Insulin resistance is associated with at least threefold increased risk for prothrombotic state in severely obese youngsters

European Journal of Pediatrics

Volumn 170, Issue 7, 2011, Pages 879-886

  Galli Tsinopoulou, Assimina ^a   Kyrgios, Ioannis ^a   Maggana, Ioanna ^a   Giannopoulou, Eleni Z ^a   Kotanidou, Eleni P ^a   Stylianou, Charilaos ^a   Papadakis, Emmanouil ^b   Korantzis, Ioannis ^b   Varlamis, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b PAPAGEORGIOU GENERAL HOSPITAL   (Greece)

Author keywords

Children and adolescents; Fibrinogen; Insulin resistance; Obesity; Plasminogen activator inhibitor 1; von Willebrand factor

Indexed keywords

FIBRINOGEN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; VON WILLEBRAND FACTOR;

ADOLESCENT; ARTICLE; BODY MASS; CHILD; CONTROLLED STUDY; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; OBESITY; PATHOGENESIS; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; SCHOOL CHILD; SEX DIFFERENCE;

ADOLESCENT; BIOLOGICAL MARKERS; BLOOD COAGULATION FACTORS; BODY MASS INDEX; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY; RISK;

EID: 79959687664     PISSN: 03406199     EISSN: 14321076     Source Type: Journal    
DOI: 10.1007/s00431-010-1370-9     Document Type: Article

References (65)

1. American Diabetes Association (2005) Diagnosis and classification of diabetes mellitus. Diab Care 28:37-42
2. Al-Daghri NM, Al-Attas OS, Alokail MS et al (2010) Relationship between resistin and aPAI-1 levels with insulin resistance in Saudi children. Pediatr Int. doi:10.1111/j.1442-200X.2010.03091.x
3. Anand SS, Yi Q, Gerstein H et al (2003) Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108:420-425 (Pubitemid 36935534)
4. Andrew M, Vegh P, Johnston M et al (1992) Maturation of the hemostatic system during childhood. Blood 80:1998-2005
5. Baker JL, Olsen LW, Sorensen TI (2007) Childhood body mass index and the risk of coronary heart disease in adulthood. N Engl J Med 357:2329-2337
6. Balagopal P, Sweeten S, Mauras N (2002) Increased synthesis rate of fibrinogen as a basis for its elevated plasma levels in obese female adolescents. Am J Physiol Endocrinol Metab 282:E899-E904 (Pubitemid 34654751)
7. Bao W, Srinivasan SR, Berenson GS (1993) Plasma fibrinogen and its correlates in children from a biracial community: the Bogalusa Heart Study. Pediatr Res 33:323-326 (Pubitemid 23095760)
8. Bao W, Srinivasan SR, Berenson GS (1996) Persistent elevation of plasma insulin levels is associated with increased cardiovascular risk in children and young adults: the Bogalusa Heart Study. Circulation 93:54-59 (Pubitemid 26006568)
9. Bastard JP, Pieroni L, Hainque B (2000) Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance. Diab Metab Res Rev 16:192-201 (Pubitemid 30410275)
10. Bibbins-Domingo K, Coxson P, Pletcher MJ et al (2007) Adolescent overweight and future adult coronary heart disease. N Engl J Med 357:2371-2379 (Pubitemid 350244535)
11. Bilgili S, Celebiler AC, Dogan A, Karaca B (2008) Inverse relationship between adiponectin and plasminogen activator inhibitor-1 in metabolic syndrome patients. Endocr Regul 42:63-68
12. Bonora E, Kiechl S, Willeit J et al (2003) Metabolic syndrome: epidemiology and more extensive phenotypic description. Cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 27:1283-1289 (Pubitemid 37281677)
13. Calabresi L, Gomaraschi M, Villa B et al (2002) Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22:656-661 (Pubitemid 34408749)
14. Cigolini M, Targher G, Bergamo Andreis IA et al (1996) Visceral fat accumulation and its relation to plasma hemostatic factors in healthy men. Arterioscler Thromb Vasc Biol 16:368-374 (Pubitemid 26084311)
15. Cole TJ, Bellizzi MC, Flegal KM, Dietz WH (2000) Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 320:1240-1243 (Pubitemid 30240471)
16. Crandall DL, Busler DE, McHendry-Rinde B et al (2000) Autocrine regulation of human preadipocyte migration by plasminogen activator inhibitor-1. J Clin Endocrinol Metab 85:2609-2614 (Pubitemid 32269222)
17. Danesh J, Collins R, Appleby P, Peto R (1998) Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 279:1477-1482 (Pubitemid 28228207)
18. Dell RB, Holleran S, Ramakrishnan R (2002) Sample size determination. ILAR J 43:207-213, Erratum in: ILAR J 2003;44:239
19. Desideri G, De Simone M, Iughetti L et al (2005) Early activation of vascular endothelial cells and platelets in obese children. J Clin Endocrinol Metab 90:3145-3152 (Pubitemid 41014267)
20. Eriksson P, Nilsson L, Karpe F, Hamsten A (1998) Very-low-density lipoprotein response element in the promoter region of the human plasminogen activator inhibitor-1 gene implicated in the impaired fibrinolysis of hypertriglyceridemia. Arterioscler Thromb Vasc Biol 18:20-26 (Pubitemid 28047594)
21. Eriksson P, Van Harmelen V, Hoffstedt J et al (2000) Regional variation in plasminogen activator inhibitor-1 expression in adipose tissue from obese individuals. Thromb Haemost 83:545-548 (Pubitemid 30201128)
22. Ernst E, Resch KL (1993) Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 118:956-963 (Pubitemid 23164134)
23. Ferguson MA, Gutin B, Owens S et al (1998) Fat distribution and hemostatic measures in obese children. Am J Clin Nutr 67:1136-1140 (Pubitemid 28259499)
24. Festa A, D'Agostino R Jr, Tracy RP et al (2002) Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes 51:1131-1137 (Pubitemid 34438360)
25. Ford ES (2003) The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the Third National Health and Nutrition Examination Survey. Atherosclerosis 168:351-358
26. Gallistl S, Sudi KM, Borkenstein M et al (2000) Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents. Int J Obes Relat Metab Disord 24:1459-1464
27. Garanty-Bogacka B, Syrenicz M, Syrenicz A et al (2005) Relation of acute-phase reaction and endothelial activation to insulin resistance and adiposity in obese children and adolescents. Neuroendocrinol Lett 26:473-479 (Pubitemid 43013717)
28. Goldberg RB (2009) Cytokine and cytokine-like inflammation markers, endothelial dysfunction, and imbalanced coagulation in development of diabetes and its complications. J Clin Endocrinol Metab 94:3171-3182
29. Greenfield JR, Campbell LV (2006) Relationship between inflammation, insulin resistance and type 2 diabetes: 'Cause or effect'? Curr Diab Rev 2:195-211
30. Gungor N, Saad R, Janosky J, Arslanian S (2004) Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 144:47-55 (Pubitemid 38091421)
31. Juhan-Vague I, Alessi MC, Vague P (1991) Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. Diabetologia 34:457-462
32. Juhan-Vague I, Alessi MC, Vague P (1996) Thrombogenic and fibrinolytic factors and cardiovascular risk in non-insulin-dependent diabetes mellitus. Ann Med 28:371-380 (Pubitemid 26268257)
33. Juhan-Vague I, Alessi MC, Morange PE (2000) Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 32(Suppl 1):78-84 (Pubitemid 32115813)
34. Kannel WB, Wolf PA, Castelli WP, D'Agostino RB (1987) Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 258:1183-1186
35. Kershaw EE, Flier JS (2004) Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 89:2548-2556 (Pubitemid 38766330)
36. Kinik ST, Özbek N, Yuce M et al (2008) PAI-1 gene 4G/5G polymorphism, cytokine levels and their relations with metabolic parameters in obese children. Thromb Haemost 99:352-356 (Pubitemid 351230966)
37. Legnani C, Maccaferri M, Tonini P et al (1988) Reduced fibrinolytic response in obese children: association with high baseline activity of the fast acting plasminogen activator inhibitor (PAI-1). Fibrinolysis 2:211-214
38. Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135-1143 (Pubitemid 34212626)
39. Lim HS, Lip GY, Blann AD (2004) Plasma von Willebrand factor and the development of the metabolic syndrome in patients with hypertension. J Clin Endocrinol Metab 89:5377-5381 (Pubitemid 39518411)
40. Lip GYH, Blann A (1997) von Willebrand factor: a marker of endothelial dysfunction in vascular disorders? Cardiovasc Res 34:255-265
41. Livadas S, Dracopoulou M, Vasileiadi K et al (2009) Elevated coagulation and inflammatory markers in adolescents with a history of premature adrenarche. Metabolism 58:576-581
42. Marshall WA, Tanner JM (1969) Variations in pattern of pubertal changes in girls. Arch Dis Child 44:291-303
43. Marshall WA, Tanner JM (1970) Variations in the pattern of pubertal changes in boys. Arch Dis Child 45:13-23
44. Matthews DR, Hosker JP, Rudenski AS (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419 (Pubitemid 15018832)
45. Mauras N, DelGiorno C, Kollman C et al (2010) Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 95:1060-1068
46. McGill HCJ, McMahan CA, Herderick EE et al (2000) Origin of atherosclerosis in childhood and adolescence. Am J Clin Nutr 72:1307S-1315S
47. Mertens I, Van Gaal LF (2002) Obesity, haemostasis and the fibrinolytic system. Obes Rev 3:85-101 (Pubitemid 34827150)
48. Mertens I, Verrijken A, Michiels JJ et al (2006) Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes (Lond) 30:1308-1314 (Pubitemid 44141622)
49. Muntner P, He J, Chen J et al (2004) Prevalence of non-traditional cardiovascular disease risk factors among persons with impaired fasting glucose, impaired glucose tolerance, diabetes, and the metabolic syndrome: analysis of the Third National Health and Nutrition Examination Survey (NHANES III). Ann Epidemiol 14:686-695 (Pubitemid 39233630)
50. Nienaber C, Pieters M, Kruger SH et al (2008) Overfatness, stunting and physical inactivity are determinants of plasminogen activator inhibitor-1activity, fibrinogen and thrombing-antithrombin complex in African adolescents. Blood Coagul Fibrinolysis 19:361-368
51. Norata GD, Grigore L, Raselli S et al (2006) Triglyceride-rich lipoproteins from hypertriglyceridemic subjects induce a proinflammatory response in the endothelium: molecular mechanisms and gene expression studies. J Mol Cell Cardiol 40:484-494
52. Ogden CL, Carroll MD, Curtin LR et al (2006) Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 295:1549-1555
53. Pannacciulli N, De Mitrio V, Marino R et al (2002) Effect of glucose tolerance status on PAI-1 plasma levels in overweight and obese subjects. Obes Res 10:717-725 (Pubitemid 135687511)
54. Sawdey MS, Loskutoff DJ (1991) Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 88:1346-1353
55. Schneider DJ, Sobel BE (1991) Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: implications for vascular disease in hyperin-sulinemic states. Proc Natl Acad Sci USA 88:9959-9963 (Pubitemid 21915754)
56. Shimomura I, Funahashi T, Takahashi M et al (1996) Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med 2:800-803 (Pubitemid 26225097)
57. Sosothikul D, Seksarn P, Lusher JM (2007) Pediatric reference values for molecular markers in hemostasis. J Pediatr Hematol Oncol 29:19-22 (Pubitemid 46143021)
58. Sudi KM, Gallistl S, Weinhandl G et al (2000) Relationship between plasminogen activator inhibitor-1 antigen, leptin, and fat mass in obese children and adolescents. Metabolism 49:890-895 (Pubitemid 30483443)
59. Taeye BD, Smith LH, Vaughan DE (2005) Plasminogen activator inhibitor-1: a common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 5:149-154 (Pubitemid 40378745)
60. Thogersen AM, Jansson JH, Boman K et al (1998) High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98:2241-2247 (Pubitemid 28533841)
61. Vague P, Juhan-Vague I, Chabert V et al (1989) Fat distribution and plasminogen activator inhibitor activity in nondiabetic obese women. Metabolism 38:913-915 (Pubitemid 19229973)
62. Valle Jiménez M, Estepa RM, Camacho RM et al (2007) Endothelial dysfunction is related to insulin resistance and inflammatory biomarker levels in obese prepubertal children. Eur J Endocrinol 156:497-502 (Pubitemid 46672652)
63. Valle M, Gascon F, Martos R et al (2000) Infantile obesity: a situation of atherothrombotic risk? Metabolism 49:672-675
64. Valle M, Martos R, Gascon F et al (2005) Low-grade systemic inflammation, hypoadiponectinemia and a high concentration of leptin are present in very young obese children, and correlate with metabolic syndrome. Diab Metab 31:55-62 (Pubitemid 40327593)
65. Zimmet P, Alberti GKMM, Kaufman F et al (2007) The metabolic syndrome in children and adolescents - an IDF consensus report. Pediatr Diab 8:299-306 (Pubitemid 47422902)